Skip to content

Mohamed Sherif

5 papers in the library · 309 citations · publishing 2011-2023

Papers

Sort Most recent Most cited

Synapses, predictions, and prediction errors: A neocortical computational study of MDD using the temporal memory algorithm of HTM

Frontiers in Psychiatry February 23, 2023 Rammohan Shukla, Mohamed Sherif, Mostafa Z. Khalil et al. 1 citation

Introduction Synapses and spines play a significant role in major depressive disorder (MDD) pathophysiology, recently highlighted by the rapid antidepressant effect of ketamine and psilocybin. According to the Bayesian brain and interoception perspectives, MDD is formalized as being stuck in affective states constantly predicting negative energy balance. To understand how spines and synapses...

mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.

Journal of Affective Disorders 2022 L. Averill, C. Averill, R. Gueorguieva et al.

Suicide is a public health crisis with limited treatment options. Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI). The parent study for the secondary pilot analyses presented here was a double-blind, cross-over trial that found pretreatment with the mechanistic target of rapamycin complex 1 (mTORC1) prolonged the antidepressant effects of ketamine. Here we...

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin

Neuropsychopharmacology February 24, 2020 Chadi G. Abdallah, Lynnette A. Averill, Ralitza Gueorguieva et al. 181 citations

Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target of rapamycin complex 1 (mTORC1). To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketamine. Twenty patients suffering a major depressive episode were randomized...

Human Laboratory Studies on Cannabinoids and Psychosis.

Biological Psychiatry April 1, 2016 Mohamed Sherif, Rajiv Radhakrishnan, Deepak Cyril D'Souza et al. 127 citations

Some of the most compelling evidence supporting an association between cannabinoid agonists and psychosis comes from controlled laboratory studies in humans. Randomized, double-blind, placebo-controlled, crossover laboratory studies demonstrate that cannabinoid agonists, including phytocannabinoids and synthetic cannabinoids, produce a wide range of positive, negative, and cognitive symptoms...

Ketamine disrupts θ modulation of γ in a computer model of hippocampus.

The Journal of neuroscience : the official journal of the Society for Neuroscience August 10, 2011 Samuel A Neymotin, Maciej T Lazarewicz, Mohamed Sherif et al.

Abnormalities in oscillations have been suggested to play a role in schizophrenia. We studied theta-modulated gamma oscillations in a computer model of hippocampal CA3 in vivo with and without simulated application of ketamine, an NMDA receptor antagonist and psychotomimetic. Networks of 1200 multicompartment neurons [pyramidal, basket, and oriens-lacunosum moleculare (OLM) cells] generated...